"These data demonstrate that 4F-PCCs are likely not to be effective in reversing DOAC
concentrations over 75 ng/mL and underscore the need for Andexxa, a unique reversal agent designed specifically to reverse Factor Xa inhibitor activity in apixaban- or rivaroxaban-treated patients experiencing a life-threatening bleed," said Scott Garland, president and chief executive officer of Portola.
The overall superiority of DOACs
by both efficacy and safety also generally extended to the subgroup of very-low-weight patients, those with weights of less than 50 kg.
Warfarin can be an inconvenient drug due to the precautions and blood tests required while taking it.
The paradox in stroke prevention is that warfarin and DOACs
used in the treatment of atrial fibrillation for ischemic stroke prevention also place a person at risk for ICH.
Coupled with the availability of DOACs
, Part D drug coverage may be an increasing source of oral anticoagulation therapy among elderly Veterans initially diagnosed with AF in the VHA, as more than 80% of patients living with AF are 65 or older and qualify for Medicare coverage.
Despite this, warfarin continues to be a medication seen in ED populations such as the elderly and those with renal impairment who may have contraindications to DOACS
and are underrepresented in many DOAC
studies (Hanley and Kowey 2015).
Apixaban is another oral direct factor (DOACs
) Xa inhibitor and has been studied in several clinical trials.
Understandably, many physicians were hesitant to prescribe DOACs
until reversal agents were developed.
In this review, we focus on the VKA warfarin and the DOACs
dabigatran and rivaroxaban and their use in NVAF in the SA state sector.
do offer value for many patients by eliminating the need for INR monitoring, there are some patients for whom warfarin remains the more appropriate course of action.
WEDNESDAY, July 11, 2018 (HealthDay News) -- Apixaban seems to be the safest direct oral anticoagulant (DOAC
) compared with warfarin, according to a study published July 4 in The BMJ.
It is now working on a testing kit for DOACs
(direct oral anticoagulants) for one major customer that is set to generate up to PS1m of extra revenue.